[Clinical studies on cefpodoxime proxetil in the pediatric fields].

Abstract

Cefpodoxime proxetil (CPDX-PR, CS-807) was given orally to 18 children with acute bacterial infections including 10 with acute tonsillitis, 3 with acute bronchitis, 1 with pneumonia, 3 with staphylococcal scalded skin syndrome and 1 with infectious impetigo. Daily dosages per kg bodyweight ranging from 7.5 to 18 mg were given in 2 or 3 divided doses per day for 5 to 15 days. Clinical responses were excellent in 3 (16.7%), good in 11 (61.1%), fair in 4 (22.2%) and poor in 0 (0%), with an overall efficacy rate of 77.8%. Good bacteriological responses were obtained in 6 out of the 7 cases from which pathogens were identified. No side effect was observed. The above results suggest that CPDX-PR is a useful new oral cephalosporin derivative for the treatment of bacterial infections in children.

• Authors: A Watanabe, M Koshinami
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 42 Issue 7 Pg. 1471-6 (Jul 1989) ISSN: 0368-2781 [Print] Japan
• PMID: 2810723 (Publication Type: English Abstract, Journal Article)

Chemical References

• cefpodoxime proxetil
• Ceftizoxime

Topics

• Acute Disease
• Administration, Oral
• Adolescent
• Bacterial Infections (drug therapy, microbiology)
• Bronchitis (drug therapy, microbiology)
• Ceftizoxime (administration & dosage, analogs & derivatives, therapeutic use)
• Chemical Phenomena
• Chemistry
• Child
• Child, Preschool
• Drug Evaluation
• Female
• Humans
• Infant
• Male
• Staphylococcal Scalded Skin Syndrome (drug therapy, microbiology)
• Tonsillitis (drug therapy, microbiology)